IMV’s current clinical strategy focuses on combination immuno-oncology therapies incorporating our lead therapeutic candidate, DPX-Survivac, for advanced ovarian cancer and diffuse large B-cell lymphoma (DLBCL). Both of these tumor types are associated with poor outcomes and are thus high unmet medical needs.
We are currently engaged in multiple immunotherapy clinical trials leveraging DPX-Survivac and metronomic cyclophosphamide with Merck’s currently marketed anti-PD-1 drug, pembrolizumab, across multiple indications. In addition, we are also evaluating the potential of DPX-Survivac as a monotherapy for certain ovarian cancer patients.
Our goal with these programs is to confirm preliminary observations that DPX-Survivac may increase the vulnerability of these hard-to-treat tumors, while improving the utility of anti-cancer activity of these advanced agents.
Early clinical investigation of a second agent, DPX-E7, in human papillomavirus (HPV) cervical cancer is being pursued in an academic collaboration led by the Dana-Farber Cancer Institute.